Literature DB >> 33537944

Addiction and Sleep Disorders.

Jonathan Ek1, William Jacobs2, Brett Kaylor2, W Vaughn McCall2.   

Abstract

Shared neurophysiology of addiction and sleep disorders results in a bidirectional interplay. Diagnosing and treating primary sleep disorders, particularly in adolescents, can prevent the development of addiction in susceptible individuals. Addressing sleep issues in early recovery, and throughout maintenance, can prevent relapse. Cannabis use for insomnia shows mixed results; assisting with onset sleep latency in early use, this subsides with chronic use and holds addiction risk. Insomnia is a primary complaint of cannabis withdrawal syndrome and a primary cause of relapse in cannabis use disorder. An ideal sleep aid would prevent relapse and have low abuse potential. Pharmaceutical and behavioral options include suvorexant, mirtazapine, trazodone, and aerobic exercise, but clinical trials are lacking to demonstrate efficacy.

Entities:  

Keywords:  Addiction; Cannabis; Insomnia; Orexin; Relapse; Sleep disorders

Year:  2021        PMID: 33537944     DOI: 10.1007/978-3-030-61663-2_12

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  67 in total

1.  The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt.

Authors:  Kimberly A Babson; Matthew Tyler Boden; Marcel O Bonn-Miller
Journal:  Addict Behav       Date:  2013-07-02       Impact factor: 3.913

2.  Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.

Authors:  Marcel O Bonn-Miller; Matthew Tyler Boden; Meggan M Bucossi; Kimberly A Babson
Journal:  Am J Drug Alcohol Abuse       Date:  2013-11-08       Impact factor: 3.829

3.  Novel Pharmacologic Approaches to Treating Cannabis Use Disorder.

Authors:  Rebecca E Balter; Ziva D Cooper; Margaret Haney
Journal:  Curr Addict Rep       Date:  2014-06-01

4.  Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users.

Authors:  Katherine A Belendiuk; Kimberly A Babson; Ryan Vandrey; Marcel O Bonn-Miller
Journal:  Addict Behav       Date:  2015-06-23       Impact factor: 3.913

Review 5.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

6.  Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.

Authors:  S Andréasson; P Allebeck; A Engström; U Rydberg
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

7.  Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence.

Authors:  Karen I Bolla; Suzanne R Lesage; Charlene E Gamaldo; David N Neubauer; Nae-Yuh Wang; Frank R Funderburk; Richard P Allen; Paula M David; Jean Lud Cadet
Journal:  Sleep Med       Date:  2010-08-03       Impact factor: 3.492

Review 8.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

9.  Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013.

Authors:  Marcus A Bachhuber; Sean Hennessy; Chinazo O Cunningham; Joanna L Starrels
Journal:  Am J Public Health       Date:  2016-02-18       Impact factor: 9.308

Review 10.  Orexin/hypocretin role in reward: implications for opioid and other addictions.

Authors:  Corey Baimel; Selena E Bartlett; Lih-Chu Chiou; Andrew J Lawrence; John W Muschamp; Omkar Patkar; Li-Wei Tung; Stephanie L Borgland
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more
  2 in total

1.  Sex Specific Sleep Parameters Among People With Substance Use Disorder.

Authors:  Caitlin E Martin; Joseph M Dzierzewski; Lori Keyser-Marcus; Emily K Donovan; Tatiana Ramey; Dace S Svikis; F Gerard Moeller
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

2.  Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series.

Authors:  Marianna Mazza; Emanuele Caroppo; Giuseppe Marano; Georgios D Kotzalidis; Carla Avallone; Giovanni Camardese; Delfina Janiri; Lorenzo Moccia; Alessio Simonetti; Luigi Janiri; Gabriele Sani
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.